Počet záznamů: 1
Prostate Health Index in Prediction of Postoperative Gleason Score Upgrading
- 1.
SYSNO ASEP 0504666 Druh ASEP A - Abstrakt Zařazení RIV Záznam nebyl označen do RIV Zařazení RIV Není vybrán druh dokumentu Název Prostate Health Index in Prediction of Postoperative Gleason Score Upgrading Tvůrce(i) Fuchsová, R. (CZ)
Topolčan, O. (CZ)
Pecen, Ladislav (UIVT-O) RID, SAI, ORCID
Dolejšová, O. (CZ)
Hora, M. (CZ)
Kučera, R. (CZ)
Eret, V. (CZ)Zdroj.dok. Clinical Chemistry and Laboratory Medicine - ISSN 1434-6621
Roč. 55, s2 (2017), S1277Poč.str. 1 s. Akce IFCC-WorldLab 2017 Datum konání 22.10.2017 - 25.10.2017 Místo konání Durban Země ZA - Jižní Afrika Typ akce WRD Jazyk dok. eng - angličtina Země vyd. DE - Německo DOI 10.1515/cclm-2017-7047 Anotace BACKGROUND-AIM: The biopsy Gleason score (GS) value affects the choice of optimal treatment of prostate cancer. Biopsy GS is, however, inaccurate. Prostate health index (PHI) in a number of studies has demonstrated a close correlation with the aggressiveness of the prostate tumor found. PHI could therefore help in choosing an optimal treatment. Aim: Evaluate the contribution of PHI in prediction of upgrading or downgrading of GS in patients with prostate cancer indicated for radical prostatectomy. METHODS: We determined the PHI (Beckman-Coulter) in a group of 320 patients from the Urology Clinic of University Hospital in Pilsen with biopsy-proven prostate cancer and indicated for radical prostatectomy. We made a comparison between the bioptic GS and the postoperative (histological) GS in relation to the PHI level. RESULTS: PHI correlates much better with the postoperative histology than with the biopsy result. The postoperative GS value was the same as the bioptic GS value in only 145 (45.3%) patients. In the case of correlation of PHI with the GS6 biopsy result, the median was 54 but only 43 in postoperative histology. 56.6% of patients with the GS6 biopsy exhibited a postoperative GS higher than 6. CONCLUSIONS: PHI is not only a diagnostic marker of prostate cancer but also a marker of aggression, and is a useful tool for urologists in predicting the upgrading of GS in patients with prostate cancer. It therefore significantly contributes to the decision on the optimal choice of treatment strategy, especially for low-risk patients with GS 6. Supported by Ministry of Health, Czech Republic - conceptual development of research organization (Faculty Hospital in Pilsen - FNPl, 00669806). Pracoviště Ústav informatiky Kontakt Tereza Šírová, sirova@cs.cas.cz, Tel.: 266 053 800 Rok sběru 2020
Počet záznamů: 1